Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis
- PMID: 31340984
- PMCID: PMC6651066
- DOI: 10.1136/bmj.l4363
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis
Abstract
Objectives: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
Design: Systematic review and meta-analysis.
Data sources: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
Study selection: Randomised controlled trials and prospective cohort studies reporting symptomatic recurrent VTE after discontinuation of anticoagulant treatment in patients with a first unprovoked VTE event who had completed at least three months of treatment.
Data extraction and synthesis: Two investigators independently screened studies, extracted data, and appraised risk of bias. Data clarifications were sought from authors of eligible studies. Recurrent VTE events and person years of follow-up after discontinuation of anticoagulant treatment were used to calculate rates for individual studies, and data were pooled using random effects meta-analysis. Sex and site of initial VTE were investigated as potential sources of between study heterogeneity.
Results: 18 studies involving 7515 patients were included in the analysis. The pooled rate of recurrent VTE per 100 person years after discontinuation of anticoagulant treatment was 10.3 events (95% confidence interval 8.6 to 12.1) in the first year, 6.3 (5.1 to 7.7) in the second year, 3.8 events/year (95% confidence interval 3.2 to 4.5) in years 3-5, and 3.1 events/year (1.7 to 4.9) in years 6-10. The cumulative incidence for recurrent VTE was 16% (95% confidence interval 13% to 19%) at 2 years, 25% (21% to 29%) at 5 years, and 36% (28% to 45%) at 10 years. The pooled rate of recurrent VTE per 100 person years in the first year was 11.9 events (9.6 to 14.4) for men and 8.9 events (6.8 to 11.3) for women, with a cumulative incidence for recurrent VTE of 41% (28% to 56%) and 29% (20% to 38%), respectively, at 10 years. Compared to patients with isolated pulmonary embolism, the rate of recurrent VTE was higher in patients with proximal deep vein thrombosis (rate ratio 1.4, 95% confidence interval 1.1 to 1.7) and in patients with pulmonary embolism plus deep vein thrombosis (1.5, 1.1 to 1.9). In patients with distal deep vein thrombosis, the pooled rate of recurrent VTE per 100 person years was 1.9 events (95% confidence interval 0.5 to 4.3) in the first year after anticoagulation had stopped. The case fatality rate for recurrent VTE was 4% (95% confidence interval 2% to 6%).
Conclusions: In patients with a first episode of unprovoked VTE who completed at least three months of anticoagulant treatment, the risk of recurrent VTE was 10% in the first year after treatment, 16% at two years, 25% at five years, and 36% at 10 years, with 4% of recurrent VTE events resulting in death. These estimates should inform clinical practice guidelines, enhance confidence in counselling patients of their prognosis, and help guide decision making about long term management of unprovoked VTE.
Systematic review registration: PROSPERO CRD42017056309.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: MC has received grants from Leo Pharma, Bristol-Myers Squibb, Bayer, Octapharma, personal fees from Sanofi Aventis, Pfizer, Boehringer Ingelheim, Leo Pharma, Bayer Pfizer, Servier, and been on the advisory board for Leo Pharma and Sanofi Aventis, outside the submitted work; CK has received grants from Bayer, outside the submitted work. JIW has received personal fees from Bayer, Boehringer Ingelheim, Bristol Myers Squibb Daiichi-Sankyo, Ionis Pharmaceuticals, Janssen, Merck, Pfizer, and Portola, outside the submitted work; SS has received grants from Boehringer Ingelheim and Octapharma, personal fees from Boehringer Ingelheim, Bayer, Daiichi Sankyo, Octapharma, Sanofi, Alnylam, and Bristol-Myers-Squibb, outside the submitted work; FC has received grants from Pfizer, and personal fees from Bayer, BMS, Aztra Zeneca, leopharma, outside the submitted work; CB has received personal fees from Bayer HealthCare, Daiichi Sankyo, Bristol Myers Squibb, and Servier, outside the submitted work; GA has received personal fees from Bristol-Myers-Squibb, Bayer Healthcare, Boehringer Ingelheim, and Daiichi Sankyo, outside the submitted work; AWAL reports being an employee of Bayer HealthCare; MHP has received personal fees from Pfizer and Daiichi Sankyo, outside the submitted work; BH reports past research from Cornerstone Research Group for methodologic advice related to the conduct of systematic reviews and meta-analysis, outside the submitted work; GP has received personal fees from Alfasigma, Pfizer, BMS, Roche, and Werfen, outside the submitted work. There are no other relationships or activities that could appear to have influenced the submitted work.
Figures
Comment in
-
Minimizing recurrent venous thromboembolism.BMJ. 2019 Jul 25;366:l4686. doi: 10.1136/bmj.l4686. BMJ. 2019. PMID: 31345836 No abstract available.
Similar articles
-
Risk of major bleeding during extended oral anticoagulation in patients with first unprovoked venous thromboembolism: a systematic review and meta-analysis protocol.Syst Rev. 2019 Oct 28;8(1):245. doi: 10.1186/s13643-019-1175-5. Syst Rev. 2019. PMID: 31661033 Free PMC article.
-
Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis.J Thromb Haemost. 2021 Nov;19(11):2801-2813. doi: 10.1111/jth.15491. Epub 2021 Aug 22. J Thromb Haemost. 2021. PMID: 34379859
-
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.Ann Intern Med. 2007 Dec 4;147(11):766-74. doi: 10.7326/0003-4819-147-11-200712040-00007. Ann Intern Med. 2007. PMID: 18056660
-
The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis.EClinicalMedicine. 2023 Sep 8;64:102194. doi: 10.1016/j.eclinm.2023.102194. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37731937 Free PMC article.
-
Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.Ann Intern Med. 2010 Oct 19;153(8):523-31. doi: 10.7326/0003-4819-153-8-201010190-00009. Ann Intern Med. 2010. PMID: 20956709 Review.
Cited by
-
Acute cor pulmonale from saddle pulmonary embolism in a patient with previous COVID-19: should we prolong prophylactic anticoagulation?Int J Infect Dis. 2020 Aug;97:299-302. doi: 10.1016/j.ijid.2020.06.039. Epub 2020 Jun 13. Int J Infect Dis. 2020. PMID: 32544670 Free PMC article.
-
Balancing the risks of recurrent venous thromboembolism and bleeding with extended anticoagulation: oh, for a crystal ball!Res Pract Thromb Haemost. 2024 Jan 18;8(1):102316. doi: 10.1016/j.rpth.2024.102316. eCollection 2024 Jan. Res Pract Thromb Haemost. 2024. PMID: 38356852 Free PMC article. No abstract available.
-
Incidence and Predictors of Recurrence and Mortality Following First Venous Thromboembolism Among the Saudi Population: Single-Center Cohort Study.Int J Gen Med. 2022 Sep 28;15:7559-7568. doi: 10.2147/IJGM.S359893. eCollection 2022. Int J Gen Med. 2022. PMID: 36199587 Free PMC article.
-
Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism.Blood Adv. 2022 Aug 9;6(15):4605-4616. doi: 10.1182/bloodadvances.2022007027. Blood Adv. 2022. PMID: 35679460 Free PMC article.
-
[Diagnosis and treatment of pulmonary embolism].Herz. 2021 Dec;46(6):589-604. doi: 10.1007/s00059-021-05078-3. Epub 2021 Nov 22. Herz. 2021. PMID: 34807296 Free PMC article. German.
References
-
- Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ 2011;342:d3036. 10.1136/bmj.d3036 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases